2005, Number 2
Rev Mex Angiol 2005; 33 (2)
Granados AJ, Chávez MC, López MA, Rodríguez VM, Yamamoto FK
PDF size: 128.39 Kb.
ABSTRACTIntroduction: This article analyzes the treatment outcomes with Fabroven extract in 402 patients with acute hemorrhoidal disease (grade I, II and III), who were included in six different studies from European countries in the Mediterranean area.
Patients and methods: The patients were treated with three to twelve capsules of Fabroven, divided in three doses every 24 hours the first three days of treatment, and in some cases, four capsules divided in two doses thereafter. The studied symptoms were: painful symptoms (discomfort, sensation of heaviness, burning, pruritus, tenesmus), accompanying symptoms (rectal bleeding, altered intestinal motility, abdominal pain), local signs (prolapse, congestive state, inflammation) and over-all severity score of symptoms. Descriptive statistical analysis was used to evaluate all results.
Results: Data analysis showed a statistical significant decrease in all scores between zero and sev-en days. The therapeutic efficacy was proven in 90% of patients and only 5% reported some adverse reaction. The pain evaluation score showed a decrease of five points on the average (p ‹ 0.0001), while the functional symptoms decreased nine points, the local symptoms 3.5 points and finally the accompanying symptoms decreased 1.5 points (p ‹ 0.001).
Conclusion: The treatment with Fabroven decreases significantly the pain, functional symptoms and inflammation in hemorrhoidal crisis of patients with disease grade I, II and III.